Tonix Pharmaceuticals’ COVID-19 vaccine, TNX-1800, has been chosen for testing in Project Next Gen, a White House and Department of Health and Human Services initiative. This project is managed by NIH and NIAID, with the goal of finding effective vaccines against infectious diseases.
The TNX-1800 vaccine uses a live virus platform that stimulates the immune system in a unique way. Unlike mRNA vaccines, this technology offers longer-lasting immunity that may also prevent transmission of the virus. The selection of TNX-1800 for this program is a testament to Tonix Pharmaceuticals’ decade of dedication to vaccine development.
Tonix’s approach offers the potential for more durable immunity and transmission prevention, which could revolutionize our approach to infectious disease control. The adaptability of this platform makes it a valuable tool for future vaccine strategies against other infectious diseases such as monkeypox, smallpox, and tuberculosis.
For more information about Tonix Pharmaceuticals and their COVID-19 vaccine, please contact Proactive Studio at +1 347-449-0879 or email them at [na-editorial@proactiveinvestors.com](mailto:na-editorial@proactiveinvestors.com).
